Loading...

Brilliant Violet 421™ anti-mouse TNF-α Antibody

Pricing & Availability
Clone
MP6-XT22 (See other available formats)
Regulatory Status
RUO
Other Names
Tumor necrosis factor-α, Cachectin, Necrosin, Macrophage cytotoxic factor (MCF), Differentiation inducing factor (DIF), TNFSF-2, TNF-a, TNF-alpha
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
MP6-XT22_BV421_TNF-a_Antibody_FC_1_100813
PMA + Ionomycin-stimulated C57BL/6 mouse splenocytes (in the presence of monensin) were stained with CD3 PE, fixed, permeabilized and then stained with TNF-α (clone MP6-XT22) Brilliant Violet 421™ (top) or rat IgG1, κ Brilliant Violet 421™ isotype control (bottom).
  • MP6-XT22_BV421_TNF-a_Antibody_FC_1_100813
    PMA + Ionomycin-stimulated C57BL/6 mouse splenocytes (in the presence of monensin) were stained with CD3 PE, fixed, permeabilized and then stained with TNF-α (clone MP6-XT22) Brilliant Violet 421™ (top) or rat IgG1, κ Brilliant Violet 421™ isotype control (bottom).
  • MP6-XT22_BV421_TNF-a_Antibody_FC_2_100813
Compare all formats See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability Save
506327 125 µL 193 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
506328 50 µg 242 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

TNF-α is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells. Many transformed cell lines also secrete TNF-α. Monomeric mouse TNF-α is a 156 amino acid protein (N-glycosylated) with a reported molecular weight of 17.5 kD. TNF-α forms multimeric complexes; stable trimers are most common in solution. A 26 kD membrane form of TNF-α has also been described. TNF-α binding to surface receptors elicits a wide array of biologic activities including: cytolysis and cytostasis of many tumor cell lines in vitro, hemorrhagic necrosis of tumors in vivo, increased fibroblast proliferation, and enhanced chemotaxis and phagocytosis in neutrophils.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse TNF-α
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For flow cytometric staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

ELISA or ELISPOT Detection: The biotinylated MP6-XT22 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified 6B8 antibody (Cat. Nos. 510802 & 510804) as the capture antibody.
ELISA Capture: The purified MP6-XT22 antibody is useful as the capture antibody in a sandwich ELISA when used in conjunction with the biotinylated Poly5160 antibody (Cat. No. 516003) as the detection antibody and recombinant mouse TNF-α (Cat. No. 575209) as the standard.
Flow Cytometry6,11,12:The fluorochrome-labeled MP6-XT22 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.
Neutralization1,5,10,16,17:The MP6-XT22 antibody can neutralize the bioactivity of natural or recombinant TNF-α. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse TNF-α bioactivity in vivo and in vitro(Cat. No. 506310). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 506332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections7-9 in vivo detection5, immunofluorescence, and immunocytochemistry.
Note: For testing mouse TNF-α in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430901) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (Neut)
  2. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20
  3. Mo X, et al. 1995. J. Virol. 69:1288.
  4. Sarawar S, et al. 1994. J. Immunol. 153:1246.
  5. Via C, et al. 2001. J. Immunol. 167:6821. (Neut)
  6. Infante-Duarte C, et al. 2000 J. Immunol. 165:6107. (FC)
  7. Jacobs M, et al. 2000. Immunology 100:494. (IHC)
  8. Marinova-Mutachieva L, et al. 1997. Clin. Exp. Immunol. 107:507. (IHC)
  9. Williams RO, et al. 2000. J. Immunol. 165:7240. (IHC)
  10. Scanga CA, et al. 1999. Infect. Immun. 67:4531. (Neut)
  11. Akilov OE, et al. 2007. J. Leukoc. Biol. 2007;10.1189/jlb.0706439. (FC)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Patole PS, et al. 2005. J. Am. Soc. Nephrol. 16:3273. PubMed
  14. Wu S, et al. 2005. Neurosci Lett. 394:158. PubMed
  15. Carlson MJ, et al. 2009. Blood 113:1365. PubMed
  16. Shivakumar P, et al. 2017. JCI Insight. 2:e88747 1. PubMed
  17. Kearney CJ, et al. 2017. Cell Death Differ. 10.1038/cdd.2017.94. PubMed
Product Citations
  1. Liu H, et al. 2022. Cell Rep Med. 3:100660. PubMed
  2. Xiao J, et al. 2023. J Clin Invest. 133: . PubMed
  3. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  4. Whyte CE, et al. 2022. Curr Protoc. 2:e589. PubMed
  5. Levra Levron C, et al. 2023. Nat Cell Biol. 25:740. PubMed
  6. Tai W, et al. 2023. Nat Commun. 14:2962. PubMed
  7. Seo YB, et al. 2023. Int J Mol Sci. 24:. PubMed
  8. Cansever D, et al. 2023. Nat Immunol. . PubMed
  9. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  10. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  11. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  12. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  13. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  14. Jiang H, et al. 2021. Oncoimmunology. 10:1943180. PubMed
  15. Laurent C, et al. 2017. Brain. 140(Pt 1):184-200. PubMed
  16. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  17. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  18. Chen Z et al. 2019. Immunity. 51(5):840-855 . PubMed
  19. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  20. Schaupp L, et al. 2020. Cell. 181(5):1080-1096. PubMed
  21. Voigt EA, et al. 2022. NPJ Vaccines. 7:136. PubMed
  22. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  23. Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed
  24. Kumagai S, et al. 2020. Immunity. 53(1):187-203.e8. PubMed
  25. Chen Z, et al. 2021. Cell. 184(5):1262-1280.e22. PubMed
  26. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  27. Prakash MD, et al. 2021. PLoS One. 16:e0247492. PubMed
  28. Tähtinen S, et al. 2022. Nat Immunol. 23:532. PubMed
  29. Silva-Cayetano A, et al. 2020. Med. 2(3):243-262.e8. PubMed
  30. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  31. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  32. Gambino F Jr, et al. 2021. Cell Reports. 35(6):109107. PubMed
RRID
AB_10900823 (BioLegend Cat. No. 506327)
AB_10900823 (BioLegend Cat. No. 506328)

Antigen Details

Structure
TNF superfamily; dimer/trimer; 17.5-150 kD (Mammalian)
Bioactivity
Paracrine/endocrine mediator of inflammatory and immune functions; selectively cytotoxic for transformed cells; endothelial cell alterations; chemoattractant
Cell Sources
Activated monocytes, neutrophils, macrophages, T cells, B cells, NK cells, LAK cells
Cell Targets
Monocytes, neutrophils, macrophages, T cells, fibroblasts, endothelial cells, osteoclasts, adipocytes, astroglia, microglia
Receptors
TNFRSF1A (TNF-R1, CD120a, TNFR-p60 Type β, p55); TNFRSF1B (TNF-R2, CD120b, TNFR-p80 Type A, p75)
Cell Type
Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. Beutler B, et al. 1988. Annu. Rev. Biochem. 57:505.
3. Beutler B, et al. 1989. Annu. Rev. Immunol. 7:625.
4. Tracey K, et al. 1993. Crit. Care Med. 21:S415.

Regulation
Processed by TACE for secretion; upregulated by interferons, IL-2, GM-CSF, substance P, bradykinin, PAF, immune complexes, and cyclooxygenase; downregulated by IL-6, TGF-β, vitamin D3, prostaglandin E2, and PAF antagonists
Gene ID
21926 View all products for this Gene ID
UniProt
View information about TNF-alpha on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Go To Top Version: 2    Revision Date: 10.14.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account